At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Gemcitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma
In Brief
A Phase 2 clinical trial evaluating Gemcitabine and Imatinib mesylate for Mesothelioma, Malignant. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient refusal or withdrawal of patient consent, or unacceptable toxicity
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesothelioma, Malignant
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedDec 2014
Primary CompletionDec 2015
Study CompletionDec 2017
TodayJul 2026
First PostedDec 1, 2014
Enrollment StartNov 1, 2014
Primary CompletionDec 1, 2015
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.6 years ago
Interventions
Gemcitabinedrug
infusion drug
Imatinib mesylatedrug
oral drug